Warhound has raised $200 million to clone and equip military working dogs, but it has no signed customers and expects to wait about two years before delivering its first dogs. That gap places a substantial biotechnology bet ahead of demonstrated demand or working-dog results.
The Texas-based defense technology startup is led by CEO David Spirk, a former Marine and former Pentagon chief data officer. Ben Lamm, CEO of Colossal Biosciences, and Anduril founder Palmer Luckey developed the concept, while Colossal licenses technology to Warhound and holds an economic interest in the company.
Warhound says it is addressing a constrained supply pipeline. According to the company, more than 80% of U.S. military working dogs are purchased from Europe, and fewer than half of purchased dogs qualify for service after an acquisition and training process lasting roughly three years.
On that basis, Warhound says approximately 200 dogs must be purchased and trained to field 100 working animals. It also places the military program at more than 2,200 dog teams. Those are company figures; current official annual purchasing and training-attrition totals are not established here.
An Army medical article reported slightly more than 1,800 active-duty military working dogs worldwide in 2022. The difference does not necessarily indicate a conflict because the figures use different dates and measures: active-duty dogs in one case and dog teams in the other.
Cloning proven dogs does not guarantee equivalent performance
Warhound plans to collect and bank genetic material from dogs that have completed training successfully, then clone selected animals. Lamm said an initial group has already been biobanked and is being edited.
The company also plans to screen for harmful genetic variants associated with muscle degeneration and other inherited diseases. Screening could address selected known variants, but Warhound has not announced results demonstrating that its process will improve qualification rates, long-term health or field performance.
Cloning reproduces nuclear DNA, not a dog’s full life history or training experience. Lamm acknowledged that limitation, saying, “training and environment will always influence performance.”
A peer-reviewed study examining the first 1,000 dogs produced by an experienced cloning group described canine cloning as technically difficult. The researchers reported average efficiency above 2%, measured as live offspring produced from transferred reconstructed eggs, and documented variation among genetically identical animals.
The study’s authors reported strong survival among cloned puppies born healthy under their care system. They also documented developmental abnormalities in some animals and said incomplete cellular reprogramming may help explain certain differences. Those findings do not establish how reliably cloned dogs will reproduce a donor’s temperament, judgment or working ability.
Welfare oversight extends beyond the working dog
The British Small Animal Veterinary Association warns that cloning can create welfare concerns for cloned animals and surrogate mothers. Its position statement on animal cloning also says evidence about clones’ long-term health remains limited and that environmental influences can produce behavioral differences from the donor animal.
That makes gestational carriers, unsuccessful pregnancies, puppy health and long-term monitoring relevant to evaluating Warhound’s plan. The company expects the American Humane Society to certify its training programs and assist with reuniting retired dogs and former handlers, but it has not detailed broader cloning-welfare safeguards.
Military oversight would also continue after a dog entered service. A 2026 Defense Department inspector general evaluation examined health care, kenneling, mental and physical wellness, training, safety, humane treatment and retirement. It found that dogs in training generally received sufficient physical activity and social and cognitive enrichment during training days.
Anduril is expected to supply eye and ear protection, body armor and integration with its Eagle Eye system. Warhound has not announced a per-dog price, and it is considering a Canine-as-a-Service arrangement under which the government would receive a continuing supply of trained dogs rather than purchase them individually.
The unresolved issue is whether Warhound can turn cloning and genetic screening into healthier, consistently capable working dogs while protecting every animal involved in production and training. Its financing can build infrastructure, but qualification rates, welfare outcomes and government adoption will determine whether the model improves the military working-dog pipeline.
What would you do if your dog were in this situation? Share your thoughts in the comments.
By Sarah Mitchell — 8 years as a local-news reporter covering animal welfare, shelters, neighborhood disputes, and public-safety pet stories.
